In a nutshell The authors aimed to determine whether cabazitaxel (Jevtana) was superior to docetaxel (Taxotere) in improving overall survival in patients with advanced, hormone-resistant prostate cancer who had not received previous treatment with chemotherapy. The authors concluded that cabazitaxel was not superior...
Read MoreIn a nutshell The aim of this study is to determine the benefit of a combination of treatments (chemotherapy, radiation therapy, and hormone therapy) in men with oligometastatic prostate cancer after prostate surgery (surgical removal of the prostate gland). The main outcome to be measured is the safety of this combination. The details...
Read More
In a nutshell The authors aimed to determine the effect of tumor-directed stereotactic body radiotherapy in prostate cancer patients with oligometastases. The authors concluded that tumor-directed stereotactic body radiotherapy was a useful treatment for both oligorecurrent and oligoprogressive castration-resistant prostate cancer. Some...
Read MoreIn a nutshell The authors aimed to determine the effectiveness of apalutamide before or after treatment with abiraterone acetate (Zytiga) and prednisone (Deltasone) in men with advanced, hormone-resistant prostate cancer. The authors concluded that apalutamide was a safe treatment option and demonstrated effectiveness against advanced,...
Read MoreIn a nutshell The authors aimed to compare outcomes after local therapy versus no local therapy in men with advanced prostate cancer (cancer that has spread outside the prostate gland). The authors concluded that local therapy resulted in better outcomes when compared to no local therapy. They also concluded that in patients who received local...
Read MoreIn a nutshell The aim of this trial is to determine the effectiveness of a combination of the chemotherapies docetaxel (Taxotere) and carboplatin (Paraplatin) in advanced (spread beyond the prostate) prostate cancer. The main outcome to be measured is the number of patients who experience a decrease of 50% in prostate specific...
Read More
In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide. Some background Treatment for metastatic...
Read MoreIn a nutshell This phase 2 trial aims to evaluate the benefit of adding tremelimumab to durvalumab, two new types of immunotherapy, for metastatic castration-resistant prostate cancer. The main outcome to be investigated is treatment response. The trial is recruiting in several locations in Canada. The details Metastatic...
Read More
In a nutshell The aim of this study was to compare the heath related quality of life (HRQOL) of patients treated with enzalutamide (Xtandi) or bicalutamide (Casodex). It was concluded that enzalutamide led to a better HRQOL in patients with metastatic castration resistant prostate cancer when compared...
Read MoreIn a nutshell This study examined if intermittent androgen deprivation therapy (IADT) reduced the risks associated with continuous androgen deprivation therapy (CADT) in advanced prostate cancer patients. It was concluded IADT reduced the risk of heart failure and fractures. Some background Advanced prostate cancer is cancer that has spread...
Read MoreIn a nutshell This study compared the benefit of combining different local therapies with hormone therapy for metastatic prostate cancer. Researchers reported a survival benefit for patients treated with surgery or intensity modulated radiation therapy (a type of radiation therapy) before hormone therapy. Some background Hormone therapy is...
Read More
In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...
Read More
